Who is sponsoring NCT05627882?

NCT05627882 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT05627882?

Interventions in NCT05627882: Forward viewing endoscope.

What condition does NCT05627882 study?

NCT05627882 studies Gastro-Intestinal Disorder.

Is NCT05627882 still recruiting?

NCT05627882 is currently completed. Last updated 2 March 2026.

Are results published for NCT05627882?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-03-02 · How we verify

NCT05627882

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP

Completed Results posted Last updated 2 March 2026

What this trial tests

trial testing Forward viewing endoscope in Gastro-Intestinal Disorder in 163 participants. Completed in 1 July 2024.

Timeline

14 October 2022

Primary endpoint
1 May 2024

1 July 2024

Quick facts

Lead sponsor	Brigham and Women's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	163
Start date	14 October 2022
Primary completion	1 May 2024
Estimated completion	1 July 2024
Sites	1 location across United States

Drugs / interventions tested

Forward viewing endoscope

Conditions studied

Gastro-Intestinal Disorder — all drugs for Gastro-Intestinal Disorder →

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Gastro-Intestinal Disorder. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Clinically Significant Endoscopic Findings Primary · Intra-procedural, up to 2 hours post-procedure

Endoscopic findings that alter medical/procedural management including: erosive disease, Barrett's esophagus, peptic ulcer, gastrointestinal malignancy, other.

Group	Value	95% CI
Standard ERCP	37

Number of Participants With Non-clinically Significant Endoscopic Findings Secondary · Intra-procedural, up to 2 hours post-procedure

Endoscopic findings that do not alter medical/procedural management including: gastritis, diverticulum, and hiatal hernia

Group	Value	95% CI
Standard ERCP	32

Sponsor's own description

This study will be a prospective, tandem-designed study to determine the proportion of clinically significant missed lesions when using a side- or oblique-viewing endoscope as compared to the standard forward-viewing endoscope. Utilizing standard endoscopy protocols in current practice at Brigham and Women's Hospital, consecutive adult patients undergoing ERCP for traditional reasons will undergo back-to-back tandem EGD and ERCP examinations. This process entails an EGD performed by an attending gastroenterologist first. Next, a second blinded attending gastroenterologist will perform ERCP immediately after index EGD. Both endoscopists will note any clinically significant findings, independent of the other providers procedural findings. Clinically significant findings defined as endoscopic findings that alter patient management (i.e., esophageal varices, peptic ulcer disease, hemorrhage, mass, etc.) during EGD and ERCP will be recorded. As previously stated, some institutions already routinely perform EGD with every ERCP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastro-Intestinal Disorder

Currently open trials in the same condition.

NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
NCT07355777 — Video Tutorial and Oral Explanation Vs Oral Explanation Alone in Colonoscopy Preparation · NA · recruiting
NCT05846802 — Gastroparesis Registry 4 · recruiting
NCT06503978 — Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders · Phase 2 · active not recruiting
NCT06271213 — The Gut-Lung Axis and Respiratory Illness in Children · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05627882 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 2 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05627882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing